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Introduction
Interferons are a family of naturally secreted proteins with
potent immunomodulatory functions [1]. They are divided
into two groups, type I IFNs (IFN-α and -β) and type II IFN
(IFN-γ) [2,3]. Generally, IFN-β and IFN-γ are thought to
play opposing roles in the regulation of inflammatory
responses: IFN-γ promotes inflammatory responses,
whereas IFN-β has mainly anti-inflammatory properties.
IFN-β downregulates the proinflammatory cytokines IL-1β
and tumor necrosis factor α (TNF-α) and enhances IL-10
and IL-1 receptor antagonist production by lymphocytes in
vitro [4–6], increases IL-1 receptor antagonist production
by fibroblast-like synoviocytes (FLS) [7], inhibits T-cell
proliferation and migration, and prevents contact-
dependent T-cell activation of monocytes [8]. IFN-β also
suppresses IFN-γ production and class II major
BSA = bovine serum albumin; CIA = collagen-induced arthritis; DMEM = Dulbecco’s modified Eagle’s medium; ELISA = enzyme-linked immunosor-
bent assay; FCS = fetal calf serum; FLS = fibroblast-like synoviocytes; GM-CSF = granulocyte/macrophage-colony-stimulating factor; HRP =
horseradish peroxidase; IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; NF = nuclear factor; OA = osteoarthritis; PBS =
phosphate-buffered saline; RA = rheumatoid arthritis; RANKL = receptor activator of NF-κB ligand; TNF = tumor necrosis factor.
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Abstract
We investigated the therapeutic potential and mechanism of
action of IFN-β protein for the treatment of rheumatoid arthritis
(RA). Collagen-induced arthritis was induced in DBA/1 mice.
At the first clinical sign of disease, mice were given daily
injections of recombinant mouse IFN-β or saline for 7 days.
Disease progression was monitored by visual clinical scoring
and measurement of paw swelling. Inflammation and joint
destruction were assessed histologically 8 days after the onset
of arthritis. Proteoglycan depletion was determined by safranin
O staining. Expression of cytokines, receptor activator of
NF-κB ligand, and c-Fos was evaluated immunohisto-
chemically. The IL-1-induced expression of IL-6, IL-8, and
granulocyte/macrophage-colony-stimulating factor (GM-CSF)
was studied by ELISA in supernatant of RA and osteoarthritis
fibroblast-like synoviocytes incubated with IFN-β. We also
examined the effect of IFN-β on NF-κB activity. IFN-β, at
0.25 µg/injection and higher, significantly reduced disease
severity in two experiments, each using 8–10 mice per
treatment group. IFN-β-treated animals displayed significantly
less cartilage and bone destruction than controls, paralleled by
a decreased number of positive cells of two gene products
required for osteoclastogenesis, receptor activator of NF-κB
ligand and c-Fos. Tumor necrosis factor α and IL-6 expression
were significantly reduced, while IL-10 production was
increased after IFN-β treatment. IFN-β reduced expression of
IL-6, IL-8, and GM-CSF in RA and osteoarthritis fibroblast-like
synoviocytes, correlating with reduced NF-κB activity. The data
support the view that IFN-β is a potential therapy for RA that
might help to diminish both joint inflammation and destruction
by cytokine modulation.
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histocompatibility complex expression by activated periph-
eral blood mononuclear cells [9]. Recent studies have also
found that IFN-β enhances expression of transforming
growth factor β1 and transforming growth factor β1
receptor type II by peripheral blood mononuclear cells [10].
In a study in the murine collagen-induced arthritis (CIA)
model, utilized extensively to evaluate novel forms of
therapy for rheumatoid arthritis (RA), DBA/1 mice were
injected intraperitoneally with fibroblasts expressing IFN-β,
resulting in continuous IFN-β delivery  in vivo, before or
after the onset of CIA [11]. A single injection of IFN-β-
secreting fibroblasts was sufficient to prevent arthritis or
ameliorate existing disease. A study of four rhesus
monkeys with CIA suggested a marked beneficial effect of
daily injections with IFN-β [4]. So far, little detailed cellular
or molecular analysis has been performed to determine
the mechanism of IFN-β action in the CIA models.
In a pilot study, six children with juvenile rheumatoid
arthritis were treated with IFN-β for 16 weeks. All tolerated
the treatment well and met the criteria for a 30% response
to treatment; three of the six met the 50% response
criteria [12]. Additionally, evaluation of 11 patients partici-
pating in a pilot study in RA showed that IFN-β treatment
significantly reduced synovial cell infiltration, as well as
IL-1β and IL-6 expression in the synovial tissue [13].
In addition to the anti-inflammatory effects of IFN-β, a
novel role in the maintenance of bone homeostasis has
recently been described. RANKL (receptor activator of
NF-κB ligand) stimulation of osteoclast precursor cells
results in their differentiation into mature bone-resorbing
osteoclasts [14]. RANKL stimulation simultaneously
induces c-Fos-dependent IFN-β expression by osteo-
clasts. Subsequent IFN-β signaling inhibits osteoclasto-
genesis, in part through negative feedback signalling to c-
Fos [14,15]. Mice deficient in IFN-β and IFN receptor
display pronounced osteopenia, and exogenous IFN-β
treatment can prevent lipopolysaccharide-induced osteo-
penia in mice. This novel protective role of IFN-β might be
important in the prevention of bone erosions, a major
problem in the treatment of RA.
We have studied whether daily systemic administration of
exogenous IFN-β in CIA in mice could have a beneficial
effect on disease activity, despite the short half-life of the
compound. Specifically, we examined the effect of IFN-β
on osteoclastogenesis in the arthritis model. In vitro
experiments were conducted to determine the effect on
the IL-1-induced production of IL-6, IL-8, and granulocyte/
macrophage-colony-stimulating factor (GM-CSF) by FLS
in RA and osteoarthritis (OA). Since gene expression of
proinflammatory cytokines is known to be under control of
the common transcription factor NF-κB [16], we studied
the effect of IFN-β on NF-κB activity.
Materials and methods
Animals
Male DBA/1 mice 10–12 weeks of age were purchased
from Bomholdgärd (Ry, Denmark). They were maintained
in a pathology-free animal facility at the Serono Pharma-
ceutical Research Institute (Geneva, Switzerland). Water
and food were provided ad libitum and all experiments
were approved by the Institutional Animal Care and Use
Committee of Switzerland.
Induction and treatment of arthritis in mice
A solution of bovine collagen type II (2 mg/ml in 0.05 M
acetic acid [Chondrex, Redmond, WA, USA]) emulsified
in an equal volume of complete Freund’s adjuvant (2 mg/ml
of  Mycobacterium tuberculosis; strain H37Ra [Difco
Laboratories, Detroit, MI, USA]) was used to induce
arthritis [17]. The mice were immunized intradermally at
the base of the tail with 100 µl of emulsion (100 µg
collagen). Arthritis usually developed between days 28
and 40 after immunization.
Mice were scored visually for the appearance of arthritis.
They were considered to have arthritis when significant
changes in redness and/or swelling were noted in the
digits or other parts of the paw. For each mouse, day 1 of
arthritis represents the first day that clinical arthritis was
detected in that mouse. The animals were randomly
assigned to one of four groups, in which they were treated
intraperitoneally with 0.25, 1.25, or 2.5 µg recombinant
IFN-β per injection or with saline as a control. Treatment
was started at the first clinical sign of disease. All groups
were treated daily for 7 days. Thereafter, the mice were
killed by cervical dislocation and the hind paws were
collected and used for further analysis. The in vivo
experiments were performed with 8–10 mice per group
and were repeated twice to ensure reproducibility.
Evaluation of arthritis activity
Mice were inspected daily for signs of arthritis by an
independent observer who was not aware of the treat-
ment. Swelling was quantified by measuring the thickness
of the hind footpad of the first arthritic paw with a caliper.
Clinical scores were assessed using an established
macroscopic system ranging from 0 to 3.5: 0 = normal,
1 = slight swelling and/or erythema, 2 = pronounced
edematous swelling, 3.5 = maximal swelling and joint
deformities with ankylosis [18]. The cumulative score for
all four paws of each mouse was used as arthritis score
(maximum of 14 per mouse) to represent overall disease
severity and progression in an animal. After 7 days of
treatment, mice were killed and their paws were
processed for histopathological evaluation.
Histology
Arthritic paws were fixed in 10% buffered formalin and
decalcified in 15% EDTA in buffered formalin (5.5%). TheR241
paws were then embedded in paraffin and 5-µm sagittal
serial sections of whole hind paws were cut and stained
with hematoxylin and eosin and examined for the degree of
synovitis and bone erosions by microscopic evaluation in a
blinded manner as described earlier [19]. Bone erosions
were scored using a semiquantitative scoring system from
0 to 4 (0 = no erosions, 4 = extended erosions and
destruction of bone). Sections were also stained with
safranin O–fast green to determine the loss of
proteoglycans. Safranin O staining was scored with a semi-
quantitative scoring system (0–3), where 0 represents no
loss of proteoglycans and 3 indicates complete loss of
staining for proteoglycans [20].
Immunohistochemistry for cell markers and cytokine
detection in synovial tissue
Immunohistochemical staining on serial sections was
performed to detect CD3-positive T cells (Novocastra Lab
Ltd, Newcastle, UK), and CD22-positive B cells (Southern
Biotech, Birmingham, AL, USA). Cytokine staining was
performed with the following goat polyclonal antibodies:
anti-TNF-α (SC-1351), anti-IL-1β (SC-1251), anti-IL-6
(SC-1265), anti-IL-10 (SC-1783), and anti-IL-18 (SC-
6179) (all purchased from Santa Cruz Biotechnology,
Santa Cruz, CA, USA). In addition, sections were stained
for RANKL and c-Fos (R&D Systems Europe Ltd,
Abingdon, UK). For control sections, the primary antibody
was omitted or irrelevant immunoglobulins were applied.
The sections were washed between all steps with
phosphate-buffered saline (PBS).
Paraffin-embedded sections (5 µm) were dewaxed and
dehydrated in a gradient of alcohols. Endogenous
peroxidase activity was quenched with 0.3% H2O2 and
0.1% sodium azide in PBS. Antigen retrieval was
performed by heating the sections for 5 minutes at 95°C
in 10 mM citric acid, pH 6.0, or 1 mM EDTA buffer, pH 8.0.
The primary antibodies were diluted in PBS containing 1%
BSA and 10% normal mouse serum at the following
dilutions: anti-CD3 (1:20), anti-CD22 (1:20), anti-TNF-α
(1:10), anti-IL-1β (1:60), anti-IL-6 (1:60), anti-IL-10 (1:80),
anti-IL-18 (1:60), anti-RANKL (1:20), and anti-c-Fos
(1:800) and incubated overnight at 4°C. Thereafter, the
sections were incubated with horseradish peroxidase
(HRP)-conjugated swine antigoat antibody (1:320, Tago,
Burlingame, CA, USA) or goat antirat HRP (1:100,
Southern Biotech, Alabama, USA) in PBS/1% BSA for
30 min at room temperature. Subsequently, the slides
were incubated for 15 min with biotinylated tyramine and
for 30 min with HRP-conjugated streptavidin. HRP activity
was detected using hydrogen peroxide as substrate and
aminoethylcarbazole as dye. Sections were briefly
counterstained with Mayer’s hemalum solution [13].
All sections were analyzed in a blinded manner by two
independent observers. After immunohistochemical
staining, expression of the different markers in the synovial
tissue of all ankle and knee joints present was scored
semiquantitatively on a 5-point scale [21]. A score of 0
represented minimal expression, while a score of 4
represented abundant expression of a marker. Minor
differences between the observers were resolved by
mutual agreement [22].
In vitro studies of the effects of IFN-β β on cytokine
production by FLS
FLS were isolated from RA and OA synovial tissue
obtained by arthroscopy. Small-bore arthroscopy (2.7-mm
arthroscope; Storz, Tuttlingen, Germany) was performed
under local anesthesia on the inflamed joint. FLS from
three RA and three OA patients were prepared as
described previously [23]. Cells used at passages 3
through 6 were seeded at 400,000 cells/well in a 6-well
plate and incubated for 24 hours in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal calf serum (FCS)
at 37°C. The next day, DMEM/10% FCS was replaced by
DMEM/0.5% FCS for 24 hours, followed by another
48 hours in the presence or absence of 125 pg/ml of
IL-1β together with various concentrations of IFN-β in
DMEM/1% FCS. Experiments were performed three times
in duplicate. Thereafter, cells were stained with trypan
blue and cell viability was assessed for potential toxic
effects of IFN-β on FLS. Supernatant was removed and
stored at –20°C until use. Supernatant, obtained as
described above, was analyzed for secreted IL-6, TNF-α,
IL-12p40, GM-CSF (all from R&D Systems Europe Ltd),
IL-18 (MBL Ltd, Nagoya, Japan), and IL-8 (CLB, Central
Laboratory of the Netherlands Red Cross Blood
Transfusion Service, Amsterdam, The Netherlands) by
sandwich ELISA.
Evaluation of apoptotis induction in FLS by IFN-β β
FLS were seeded at 100,000 cells/well and incubated for
18 hours in the presence or absence of 125 pg/ml of
IL-1β together with various concentrations of IFN-β or
150 µM H2O2. Cells were trypsinized and counted, and
cytospins were performed. After the slides were dried,
Diff-Quik staining (Dade Behring, Düdingen, Switzerland)
was performed and the percentage of pyknotic nuclei was
calculated by microscopic analysis to represent the
amount of apoptosis. This technique is comparable to the
Pappenheim technique by Giemsa–May–Grünwald staining.
FLS transfection and NF-κ κB activation analysis
FLS from RA patients were transfected with 1 µg each of
NF-κB/luciferase reporter construct and a renilla
luciferase construct under the control of the thymidine
kinase promoter. FLS cultured at 50,000 cells/well were
transfected with 2 µg of DNA mix and 6 µl of Fugene 6
transfection reagent (Roche, Indianapolis, IN, USA) in
DMEM overnight. Thereafter, transfected FLS were
incubated for 18 hours in the presence or absence of
Available online http://arthritis-research.com/content/6/3/R239125 pg/ml of IL-1β together with various concentrations of
IFN-β before measurement of luciferase activity (Dual
Luciferase Assay System; Promega, Leiden, The
Netherlands). NF-κB-dependent luciferase activity was
normalized to renilla luciferase activity to account for
potential variations in transfection efficiency and/or
nonspecific transcriptional effects. Experiments were
performed three times.
Statistical analysis
The following nonparametric tests were used: the
Kruskal–Wallis test for several group means (comparing
histologic scores and the scores for expression of
different markers in more than two therapy groups), followed
by the Mann–Whitney U test for comparison of two
groups [22].
Results
IFN-β β therapy inhibits arthritic activity and synovial
inflammation
To examine whether IFN-β therapy could be effective in
the treatment of CIA, mice were given a daily intra-
peritoneal injection with various dosages of IFN-β or saline
for 7 days. All animals were treated at the first clinical sign
of disease. Although disease started on different days
after immunization, we did not observe a relation between
clinical response and time of onset of disease. All groups
treated with IFN-β showed a 50% decrease in arthritis
score and an approximately 70% decrease in paw
swelling compared to controls (P = 0.005) (Fig. 1a,b).
There was no clear dose dependency, suggesting that all
dosages were in the therapeutic range with regard to
effects on clinical signs of arthritis. An additional
experiment in which animals were treated at the first
clinical sign of disease for 14 days showed the same
beneficial effect of treatment (data not shown).
The effect of IFN-β treatment on synovial inflammation was
also assessed by histology. A marked reduction in the
number of inflammatory cells was found for all IFN-β-
treated groups (Fig. 2a): a statistically significant
(P = 0.04) reduction of inflammatory cells was observed in
mice treated with the 1.25- or 2.5-µg doses; there was
also a tendency towards decreased cell inifiltration in the
mice treated with the 0.25-µg dose, but this did not reach
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Figure 1
Effect of systemically delivered IFN-β at the onset of arthritis in mice
with collagen-induced arthritis. (a) Clinical score (mean ± SEM) was
assessed on a scale of 0 to 3.5 (as described in Materials and
methods), and (b) hind paw swelling (mean ± SEM) of the first arthritic
paw was monitored during the course of disease using calipers. On
day 7 after the start of the treatment, differences between all treatment
groups and the control group were statistically significant (P = 0.005)
(Kruskal–Wallis test). Arrows mark the first day of treatment.
*Statistically significant difference. SEM, standard error of the mean.
Figure 2
Representative histologic staining (hematoxylin and eosin; ×100) of
the ankle joints in mice with collagen-induced arthritis (CIA). At day 7
after the start of treatment with IFN-β, mice were sacrificed and
subjected to histopathological examination. (a) In the control CIA mice
treated with saline, massive cellular infiltration and erosion of bone
were observed in the ankle joint. In CIA mice treated with the highest
dose of IFN-β (2.5 µg per injection per mouse), limited hyperplasia of
the intimal lining layer and cell infiltration of the synovial sublining were
detected and a decrease in bone erosions was observed. (b) Infiltration
of inflammatory cells of the joints was scored from 0 to 4 in a blinded
manner as described in Materials and methods. A significant reduction
in inflammatory cells was observed for the treatment groups treated
with 2.5 µg and 1.25 µg IFN-β in comparison with controls (P = 0.04).
*Statistically significant difference.statistical significance (Fig. 2b). While the total numbers
of infiltrating T and B lymphocytes were similar between
control and IFN-β-treated mice (P = 0.4) (Fig. 3a,b), we
observed an approximately 50% reduction in the number
of macrophages (P = 0.04) (Fig. 3c) and a 70% decrease
in the number of granulocytes (P = 0.009) (Fig. 3d) in the
mice treated with the highest dose (2.5 µg) of IFN-β.
IFN-β β treatment inhibits cartilage and bone degradation
Next, cartilage destruction was assessed by safranin O
staining on paraffin sections of joints from CIA mice
treated with the two highest doses of IFN-β, or with saline
as control. Scores for proteoglycan staining were similar in
the group given 1.25 µg IFN-β/day and the control group
(Fig. 4b). However, in CIA mice treated with the highest
dose of IFN-β (2.5 µg IFN-β/day) we observed a 70%
decrease in scores for proteoglycan depletion in cartilage
(P = 0.03).
Bone destruction was assessed by staining of paw
sections with hematoxylin and eosin to assess erosion
scores. Analysis of the ankle and knee joints revealed a
77% reduction in the mean scores for bone erosions in
mice treated with the two highest doses of IFN-β in
comparison with controls (P = 0.02), whereas the lowest
treatment dose did not result in a significant decrease in
bone erosions (Fig. 5a).
Having shown the protective effect of IFN-β treatment on
bone degradation, we analyzed the number of cells
positive for RANKL and c-Fos, molecules that are intimately
involved in osteoclast function. We found a 50% decrease
in the number of RANKL-positive cells (P = 0.07) and a
50% reduction in the number of c-Fos-positive cells
(P = 0.04) in the animals treated with the highest dose of
IFN-β (Fig. 5b,c, respectively). In addition, we found a
positive correlation between osteoclast-like cells defined
by morphology and the number of cells expressing c-Fos
(data not shown).
IFN-β β modulates the cytokine profile in inflamed
synovial tissue.
To provide more insight into the mechanism by which IFN-
β therapy exerts its beneficial effects, we examined
cytokine expression at the site of inflammation. Several
proinflammatory cytokines play a crucial role in the
Available online http://arthritis-research.com/content/6/3/R239
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Figure 3
T-cell, B-cell, macrophage, and granulocyte expression in the synovium of mice with collagen-induced arthritis, after 7 days of IFN-β therapy,
detected by immunohistochemistry. Sections were scored for CD3 and CD22 as described in Materials and methods. Macrophages and
granulocytes were evaluated by morphology. (a) CD3 expression. (b) CD22 expression. (c) Macrophage expression. (d) Granulocyte expression.
No significant differences between treated animals and controls were observed for CD3 and CD22 expression (P = 0.4 for both). Statistically
significant differences were observed for macrophage and granulocyte expression between IFN-β-treated mice and saline-treated mice (P = 0.04
and 0.009, respectively). *Statistically significant difference.pathogenesis of RA, including IL-1, TNFα, and IL-6 [24],
while the anti-inflammatory cytokine IL-10 has been found
to be protective [25]. Recently, the presence of IL-18 in
RA synovium and its role in the development and
maintenance of inflammatory arthritis have been shown
[26]. To determine whether alterations in the expression of
these mediators might contribute to the protective effect
of IFN-β treatment on the development of CIA in mice, we
performed an immunohistochemical analysis of cytokine
expression on paraffin sections of mouse paws. The
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Figure 4
Representative histologic staining with safranin O–fast green (×100)
of the ankle joint of mice with collagen-induced arthritis (CIA) mice
after daily IFN-β therapy for 7 days. (a) (Upper panel) In CIA mice
treated with saline as controls, hardly any safranin O staining was
observed in the ankle joints. (Lower panel) In CIA mice treated daily
with 2.5 µg IFN-β, significantly less loss of safranin O staining was
observed, indicating inhibition of cartilage breakdown. (b) Histologic
analysis of cartilage in CIA in mice after 7 days of IFN-β therapy. Hind
paw sections were stained with safranin O–fast green, which stains
the cartilage proteoglycans. Sections were scored in a blinded manner
on a 4-point scale as described in Materials and methods. Significantly
less loss of safranin O staining was observed in the animals treated
with IFN 2.5 µg than in controls (P = 0.03), indicating inhibition of
cartilage destruction. *Statistically significant difference.
Figure 5
Histologic analysis of bone erosions in mice with collagen-induced
arthritis (CIA) after treatment with IFN-β. Mice were treated with the
indicated concentrations of IFN-β for 7 days starting when the first
clinical signs of arthritis were observed. Hind paws were taken for
histology. (a) Bone erosions were scored in a blinded manner on a
scale of 0 to 4 as described in Materials and methods. A significant
reduction in bone erosions was observed in the animals treated with
2.5 µg and 1.25 µg IFN-β per injection/mouse in comparison with
controls (P = 0.02); results are means ± SEM. Immunohistochemical
analysis of the number of cells positive for RANKL (receptor activator
of NF-κB ligand) and c-Fos after 7 days of IFN-β treatment in CIA
mice. Sections were scored on a 4-point scale. (b) RANKL staining; a
decrease of RANKL-positive cells was observed in the group of
animals treated with 2.5 µg IFN-β, although not statistically significant
(P = 0.07). (c) c-Fos staining; the number of c-Fos-positive cells was
significantly reduced in the mice treated with daily 2.5 µg per injection
IFN-β (P = 0.04). *Statistically significant difference. SEM, standard
error of the mean.expression of IL-6 and of TNF-α was decreased (50% and
55% respectively) in mice treated with 2.5 µg IFN-β for
7 days in comparison with saline-treated mice (P = 0.02
and  P = 0.03, respectively). IL-18 and IL-1β expression
also tended to be lower in IFN-β-treated animals, but the
differences did not reach statistical significance. IL-10
expression was increased by approximately 70% in the
synovium of IFN-β-treated mice (Fig. 6). No significant
effects were observed for the lower dosage of IFN-β.
IFN-β β reduces cytokine expression in FLS
In vitro experiments revealed that IL-1β-induced production
of IL-6, IL-8, and GM-CSF in RA as well as OA FLS was
inhibited by IFN-β (Fig. 7). No clear differences between
RA and OA FLS were found. The highest reduction (40%,
65%, and 65%, respectively) (P = 0.0005, 0.0007, and
0.003, respectively) was found for the dosage of
1.22 µg/ml IFN-β, corresponding to the injection dosage
required for optimal serum concentration of IFN-β in
healthy human volunteers [27].
To exclude the possibility that the observed differences in
cytokine secretion were the result of increased cell death,
apoptotic cells were counted at the end of each
experiment using Diff-Quik staining of cytospins. Although
treatment of FLS with hydrogen peroxide readily induced
apoptosis, no significant induction of apoptosis was
observed after IFN-β treatment (data not shown).
IL-1-dependent production of IL-6, IL-8, and GM-CSF in
FLS is critically dependent upon activation and nuclear
translocation of NF-κB. Therefore, we assessed the
effects of IFN-β treatment on IL-1-dependent NF-κB
activity after transfection of RA FLS with an NF-κB-
dependent luciferase reporter construct. We observed a
tendency towards lower NF-κB activity with increasing
concentrations of IFN-β used (a 45% decrease for
1.22 µg/ml IFN-β), indicating that the reduced cytokine
production we observed may be explained in part by the
inhibition of NF-κB activity by IFN-β in RA FLS (Fig. 8).
Discussion
The results presented in this study demonstrate for the
first time that daily administration of exogenous IFN-β
starting at the onset of disease in the murine CIA model
reduces synovial inflammation and protects against
cartilage and bone destruction. The fact that clinical
effects, but not histologic changes, were detected at the
lowest dosage might be explained by the relative lack of
sensitivity to change of semiquantitative histologic analysis.
IFN-β treatment also resulted in a reduction in pro-
inflammatory cytokine expression by synovial cells, which
could be explained in part by inhibition of NF-κB activity.
Of importance, histologic examination revealed a
reduction in the number of osteoclasts in the animals
treated with IFN-β, correlating with a reduction in cartilage
and bone destruction, suggesting that osteoclastogenesis
is inhibited by the presence of IFN-β. Recent studies by
Takayanagi and colleagues have described an essential
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Figure 6
(a) Cytokine expression measured by immunohistochemistry after
7 days of systemic IFN-β treatment in mice with collagen-induced
arthritis (CIA). Tumor necrosis factor (TNF)-α, IL-18, IL-1β, IL-10, and
IL-6 were scored (mean ± SEM) in a blinded manner on a scale of 0 to
4 as described in Materials and methods. A statistically significant
reduction of the proinflammatory cytokines TNF-α and IL-6 (P = 0.03
and 0.02, respectively) was observed in the mice treated with 2.5 µg
IFN-β in comparison with controls. The expression of IL-18 and IL-1β
was reduced in the animals treated with the highest dose of IFN-β, and
the expression of IL-10 was higher than in controls. These differences
did not reach statistical significance. No clear-cut differences were
observed in the animals treated with 1.25 µg IFN-β in comparison with
controls. Bars represent mice treated with 2.5 µg IFN-β (grey), 1.25 µg
IFN-β (white) or saline (black). (b) Representative immunohistologic
staining showing TNF-α expression in the ankle joints in CIA mice after
7 days of IFN-β treatment, assessed by immunohistochemistry. (Upper
panel) TNF-α expression in CIA mice treated with saline; abundant
expression of TNF-α was observed in the ankle joint. (Lower panel) TNF-
α expression in CIA mice treated with 2.5 µg IFN-β; in the group treated
with the highest dose of IFN-β, only a few positive cells for TNF-α were
observed. *Statistically significant difference. SEM, standard error of the
mean.role for IFN-β in the negative regulation of RANKL- and
c-Fos-dependent osteoclast differentiation [14]. In agree-
ment with their predictions, decreases in osteoclasto-
genesis observed in arthritic mice treated with IFN-β were
paralleled by a decrease in the number of RANKL- and
c-Fos-positive cells. In addition to effects on osteoclasto-
genesis, IFN-β might also affect osteoclast activity directly.
Src tyrosine kinase function (and two of its targets, Ras
and Cbl) are required for bone resorption by osteoclasts
[28–30]. It was previously reported that IFN-β has
negative effects on tyrosine kinase signalling pathways in
HL-60 cells [31]. Thus, IFN-β treatment may represent a
potentially therapeutic strategy in inhibiting bone degrada-
tion in arthritis.
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Figure 7
IL-6, IL-8, and GM-CSF (granulocyte/macrophage-colony-stimulating factor) production in synoviocytes from patients with rheumatoid arthritis (RA)
and osteoarthritis (OA) after incubation with increasing concentrations of IFN-β, measured in supernatant of fibroblast-like synoviocytes using
enzyme-linked immunosorbent assay. Decreased production of (a) IL-6, (b) IL-8, and (b) GM-CSF in RA and OA fibroblast-like synoviocytes after
48 hours’ incubation with increasing concentrations of IFN-β.Further experiments were carried out to determine the
effect of IFN-β on the total numbers of T cells, B cells,
macrophages, and granulocytes. We found no clear
differences in the total numbers of T cells and B cells in
the animals treated with IFN-β in comparison with controls
as assessed by immunohistochemistry. Recent studies
have proposed that endogenous IFN-β production in RA
might theoretically promote inflammation, as IFN-β can
promote T-cell and neutrophil survival in vitro [32]. While
our studies did not specifically address the effects of
exogenous IFN-β on T-cell survival in the synovial joint, we
did not observe an increase in T-cell numbers, and any
potential anti-apoptotic effect did not prevent a beneficial
therapeutic effect of IFN-β in vivo.
In contrast to the lack of effect on T- and B-cell infiltration,
morphological analysis revealed a tendency towards a
decreased number of macrophages and a significant
reduction in the number of granulocytes in animals treated
with IFN-β. Although one study has reported that IFN-β
induces apoptosis in a monocytic leukaemia cell line [33],
on the basis of that study, it is unclear whether IFN-β is
influencing monocyte recruitment, survival, and/or
retention in the synovial joint.
Alternatively, IFN-β may inhibit inflammatory cell infiltration
indirectly, via suppression of FLS and/or monocyte
activation. Our data demonstrated statistically significant
modulation of proinflammatory and anti-inflammatory cyto-
kine production in animals treated with IFN-β. We found a
statistically significant reduction of TNF-α and IL-6
expression and an increase in IL-10 production in the
animals treated with the highest dose IFN-β. TNF-α plays
an important role in the pathogenesis of CIA as well as
RA. Treatment with TNF-α blockade has been shown to
be effective in both CIA and RA [34–36]. The reduced
expression of IL-6 could also be beneficial, as IL-6 may
inhibit bone formation and induce bone resorption through
its stimulatory effects in osteoclasts, and it is known that
IL-6 knockout mice do not develop bone erosions.
Moreover, it has been suggested that treatment with anti-
IL-6 receptor antibody may be effective in RA patients
[37]. Of interest, IL-10 production was increased in the
IFN-β-treated animals. IL-10 may be a potent anti-
inflammatory cytokine, achieving the effect through
suppression of TNF-α, IL-6, and IL-1 production by
activated macrophages [38]. A trend towards clinical
improvement has been suggested in RA patients treated
with recombinant human IL-10 [39].
It has been shown previously that IFN-β has an inhibitory
effect on the production of TNF-α by lipopolysaccharide-
stimulated macrophages from mouse bone marrow [11].
In this study, we show for the first time that IFN-β can
decrease the production of IL-6, IL-8, and GM-CSF by
stimulated FLS from RA and OA patients. Although the
molecular signalling mechanism underlying this inhibitory
effect requires further elucidation, preliminary evidence
presented here suggests that IFN-β acts at least in part via
inhibition of NF-κB activity induced by IL-1.
The potential effects of IFN-β were previously investigated
in CIA in mice by IFN-β gene therapy [11]. Fibroblasts
from DBA/1 mice were infected with a retrovirus express-
ing murine IFN-β and were injected intraperitoneally into
CIA mice before and after the onset of arthritis, leading to
continuous IFN-β delivery. A significant decrease in
inflammation was observed after IFN-β gene therapy both
before and after the onset of disease. At present, viral and
nonviral vectors that are used for gene therapy have
limited applications for use in humans. Therefore, our
approach using daily injections with murine IFN-β could
have the advantage of easily translating results into RA
patients. However, it remains to be shown whether the
exciting biological effects described in the present study
can be achieved in RA patients if IFN-β is administered
only three times weekly, in accordance with the regular
treatment regimen in patients with multiple sclerosis. A
recent pilot study, which was not designed to evaluate
clinical efficacy, did not suggest clinical improvement after
IFN-β treatment three times weekly [40]. It is conceivable
that more frequent injections as in the present study, higher
doses, or the use of compounds with a longer half-life is
required to induce clinically meaningful effects in RA
patients. Obviously, although animal arthritis models are
very useful for screening interesting compounds, the results
are not necessary identical to those obtained in RA patients.
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Figure 8
Relative NF-κB activity measured in NF-κB-transfected rheumatoid
arthritis synoviocytes after incubation with increasing concentration of
IFN-β. Unactivated fibroblast-like synoviocytes showed low NF-κB activity.
IL-1β-induced NF-κB activity revealed a trend towards inhibition after
incubation with IFN-β in increasing concentrations.Conclusion
The marked reduction of CIA in mice, the changes in
synovial tissue from mice with CIA after IFN-β therapy, and
the effects on synoviocytes from RA patients all support
the view that IFN-β treatment has immunomodulating
effects and might have a beneficial effect on joint
inflammation and, perhaps more importantly, on bone
destruction in RA patients.
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